Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alterity Therapeutics Limited - American Depositary Shares
(NQ:
ATHE
)
4.420
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 13, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,132
Open
4.420
Bid (Size)
4.270 (7)
Ask (Size)
4.400 (1)
Prev. Close
4.420
Today's Range
4.420 - 4.420
52wk Range
1.001 - 5.870
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Alterity Therapeutics Raises A$40.0 million in Placement
February 10, 2025
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Wondering what's happening in today's after-hours session?
February 07, 2025
The US market regular session of Friday is over, let's have a look at the top gainers and losers in the after hours session today.
Via
Chartmill
Performance
YTD
+18.50%
+18.50%
1 Month
+33.53%
+33.53%
3 Month
+277.78%
+277.78%
6 Month
+220.29%
+220.29%
1 Year
+123.23%
+123.23%
More News
Read More
Nasdaq Moves Lower; Meta Platforms Posts Strong Sales
January 30, 2025
Via
Benzinga
What's Going On With Alterity Therapeutics Shares Thursday?
January 30, 2025
Via
Benzinga
Dow Jumps Over 100 Points; Tesla Earnings Miss Views
January 30, 2025
Via
Benzinga
Topics
Earnings
Stocks
Exposures
Financial
US Equities
Alterity Therapeutics Stock Doubles Premarket On Positive MSA Trial Results: Retail Excitement Soars
January 30, 2025
Via
Stocktwits
Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy
January 30, 2025
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
January 30, 2025
Via
Benzinga
Why Meta Platforms Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
January 30, 2025
Via
Benzinga
Appendix 4C – Q2 FY25 Quarterly Cash Flow Report
January 24, 2025
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones
January 09, 2025
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy
December 04, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
November 29, 2024
Via
Benzinga
Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary
November 19, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium
November 12, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434
November 06, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Appendix 4C – Q1 FY25 Quarterly Cash Flow Report
October 31, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024
October 14, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting
October 11, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®
October 02, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer
September 30, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®
September 23, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Appendix 4C – Q4 FY24 Quarterly Cash Flow Report
July 31, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics to Present at MST Financial Webinar
July 24, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
July 17, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.